Previous close | 194.95 |
Open | 196.43 |
Bid | 198.11 x 1300 |
Ask | 206.21 x 1300 |
Day's range | 194.91 - 198.89 |
52-week range | 165.75 - 254.94 |
Volume | |
Avg. volume | 983,425 |
Market cap | 36.942B |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | 94.71 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RESEARCH TRIANGLE PARK, N.C., March 14, 2023--In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Tr
RESEARCH TRIANGLE PARK, N.C., March 01, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.
RESEARCH TRIANGLE PARK, N.C., February 23, 2023--IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.